Sanofi to invest in new insulin production base in Beijing

French pharma giant Sanofi will invest some 1 billion euros ($1.05 billion) to establish a new insulin production base in Beijing, according to the Beijing Economic-Technological Development Area (BDA).

Sanofi signed a memorandum of cooperation on Monday with the Beijing Municipal Bureau of Economy and Information Technology and the BDA Administrative Committee to build the facility in the city's southern area of Yizhuang. This will be Sanofi's fourth production-and-supply base in China and represents its largest single investment in the country to date.

Sanofi Chief Executive Paul Hudson noted that the new production base featuring advanced automated production technologies, cutting-edge digital integrated management systems and sustainable environmental standards will further enhance the company's supply-chain resilience and efficiently address the growing needs of diabetes patients.